<DOC>
	<DOC>NCT00095342</DOC>
	<brief_summary>The primary objective of this clinical research study is to compare the efficacy and the safety of 3 dose levels of oral TMI-005 in comparison with placebo in subjects with active Rheumatoid Arthritis (RA) who have been receiving stable doses of Methotrexate (MTX).</brief_summary>
	<brief_title>Study Evaluating TMI-005 in Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Meet American College of Rheumatology (ACR) criteria for RA Have active RA Disease duration of at least 6 months Disease onset at &gt; 16 years of age. Any prior use of antiTNF alpha biologics, rituximab, receipt of antiCD4 or diphtheria interleukin2 fusion protein or other immunosuppressive biologics (except for anakinra) Largely or wholly incapacitated with the subject bedridden or confined to a wheelchair, permitting limited or no selfcare Pregnant or breastfeeding women or women planning to become pregnant during the study or within 12 weeks after the last dose of test article</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>